Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Gardner

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
BMC Medical Education|December 11, 2012
Effectiveness of contact-based education for reducing mental illness-related stigma in pharmacy studentsScott B Patten, Alfred Remillard, Leslie Phillips, et al.
BMC Health Services Research|October 13, 2016
From personal crisis care to convenience shopping: an interpretive description of the experiences of people with mental illness and addictions in community pharmaciesAndrea L Murphy, Ruth Martin-Misener, Stan P Kutcher, et al.
SAGE Open Medicine|February 8, 2019
A survey of Canadian and Australian pharmacists' stigma of suicideAndrea L Murphy, Claire L O'Reilly, Randa Ataya, et al.
Healthcare Policy = Politiques De Sante|July 20, 2019
Policies for Deprescribing: An International Scan of Intended and Unintended Outcomes of Limiting Sedative-Hypnotic Use in Community-Dwelling Older AdultsJames Shaw, Andrea L Murphy, Justin P Turner, et al.
JBI Evidence Synthesis|November 9, 2020
Driving performance assessments for benzodiazepine receptor agonist-related impairment: a scoping review protocolAndrea L Murphy, Sophie M Peltekian, Melissa Helwig, et al.
Social Psychiatry and Psychiatric Epidemiology|June 25, 2018
Community pharmacists' experiences and people at risk of suicide in Canada and Australia: a thematic analysisAndrea L Murphy, Randa Ataya, Dani Himmelman, et al.
Neuropsychiatric Disease and Treatment|June 24, 2008
Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disordersStan Kutcher, Sarah J Brooks, David M Gardner, et al.
Exploratory Research in Clinical and Social Pharmacy|December 5, 2024
A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonistsAndrea L Murphy, Korolos Sawires, Sophie M Peltekian, et al.
Annals of General Psychiatry|January 26, 2013
Evidence review and clinical guidance for the use of ziprasidone in CanadaDavid M Gardner, Andrea L Murphy, Stan Kutcher, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 18, 2015
Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorderDaniel A Gorman, David M Gardner, Andrea L Murphy, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
BMC Medical Education|December 11, 2012
Effectiveness of contact-based education for reducing mental illness-related stigma in pharmacy studentsScott B Patten, Alfred Remillard, Leslie Phillips, et al.
BMC Health Services Research|October 13, 2016
From personal crisis care to convenience shopping: an interpretive description of the experiences of people with mental illness and addictions in community pharmaciesAndrea L Murphy, Ruth Martin-Misener, Stan P Kutcher, et al.
SAGE Open Medicine|February 8, 2019
A survey of Canadian and Australian pharmacists' stigma of suicideAndrea L Murphy, Claire L O'Reilly, Randa Ataya, et al.
Healthcare Policy = Politiques De Sante|July 20, 2019
Policies for Deprescribing: An International Scan of Intended and Unintended Outcomes of Limiting Sedative-Hypnotic Use in Community-Dwelling Older AdultsJames Shaw, Andrea L Murphy, Justin P Turner, et al.
JBI Evidence Synthesis|November 9, 2020
Driving performance assessments for benzodiazepine receptor agonist-related impairment: a scoping review protocolAndrea L Murphy, Sophie M Peltekian, Melissa Helwig, et al.
Social Psychiatry and Psychiatric Epidemiology|June 25, 2018
Community pharmacists' experiences and people at risk of suicide in Canada and Australia: a thematic analysisAndrea L Murphy, Randa Ataya, Dani Himmelman, et al.
Neuropsychiatric Disease and Treatment|June 24, 2008
Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disordersStan Kutcher, Sarah J Brooks, David M Gardner, et al.
Exploratory Research in Clinical and Social Pharmacy|December 5, 2024
A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonistsAndrea L Murphy, Korolos Sawires, Sophie M Peltekian, et al.
Annals of General Psychiatry|January 26, 2013
Evidence review and clinical guidance for the use of ziprasidone in CanadaDavid M Gardner, Andrea L Murphy, Stan Kutcher, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 18, 2015
Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorderDaniel A Gorman, David M Gardner, Andrea L Murphy, et al.
Pageof 7